Skip to main content
S&P 5007,713.14+1.91%DOW53,304.58+2.93%NASDAQ25,923.13+2.17%BTC$80,362.00+3.59%ETH$2,423.15+5.62%GOLD$4,079.00+3.52%OIL$87.95-8.47%
Smart Investors Daily
SID Premium
FU

NASDAQ · FULC

Fulcrum Therapeutics, Inc.

Healthcare · Biotechnology

$3.74

Up+$0.02 (+0.40%)

Updated Nov 4, 2026, 5:51 PM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
692.63M
P/E ratio
-11.27
Dividend yield
0.00%
52-week range
$2.83 – $8.37
Volume
1.37M
Avg. volume
1.17M

Price performance · FULC

FULC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

FULC closed at $3.74 after 21 trading sessions, up 1.36% for the selected period.

Last close
$3.74
Period change
+1.36%
Period low
$3.64
Period high
$3.77
Daily close
View OHLC price history
FULC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$3.76$3.765$3.69$3.741.37M
Nov 2, 2026$3.72$3.725$3.64$3.651.21M
Oct 30, 2026$3.74$3.755$3.68$3.71933.22K
Oct 29, 2026$3.77$3.795$3.73$3.771.62M
Oct 28, 2026$3.69$3.77$3.67$3.752M
Oct 27, 2026$3.66$3.735$3.63$3.701.9M
Oct 26, 2026$3.69$3.69$3.63$3.64773.33K
Oct 23, 2026$3.68$3.69$3.64$3.681.07M
Oct 22, 2026$3.71$3.735$3.66$3.682.31M
Oct 21, 2026$3.72$3.745$3.70$3.70923.78K
Oct 20, 2026$3.71$3.75$3.695$3.72757.12K
Oct 19, 2026$3.67$3.72$3.66$3.701.19M
Oct 16, 2026$3.68$3.685$3.64$3.651.39M
Oct 15, 2026$3.71$3.725$3.66$3.671.23M
Oct 14, 2026$3.67$3.715$3.65$3.671.66M
Oct 13, 2026$3.75$3.75$3.675$3.681.46M
Oct 12, 2026$3.77$3.77$3.73$3.751.61M
Oct 9, 2026$3.75$3.785$3.72$3.771.8M
Oct 8, 2026$3.66$3.775$3.66$3.752.63M
Oct 7, 2026$3.70$3.72$3.67$3.671.04M
Oct 6, 2026$3.72$3.725$3.68$3.69757.03K

Latest FULC news

The latest Smart Investors Daily articles mentioning FULC.

Stock researchCompany · Overview

FULC research

Overview

Company profile and research snapshot.

Company profile

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$20.71
Implied upside
—
Analysts
15
FULC recent ratings
DateFirmRatingTarget
Jun 3, 2026JP MorganUnderweight—
Jun 2, 2026Truist SecuritiesHold—
Jun 2, 2026Piper SandlerUnderweight—
Jun 2, 2026StifelHold—
Jun 2, 2026Leerink PartnersMarket Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 27, 2026

Slate Medicines Starts Migraine Treatment Study

By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company’s subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending dose is being conducted in Australia with topline safety data estimated by mid-2027, it stated. READ MORE Final Agenda: 2nd LA CorpGov […] The post Slate Medicines Starts Migraine Treatment Study appeared first on ExecEdge.

Yahoo · Aug 5, 2026

Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit

The updated analyst framework for Fulcrum Therapeutics lifts the Fair Value estimate from US$5.43 to US$5.83 per share. This shift in price target sits against a backdrop of sharply changed Street commentary after the decision to discontinue pociredir, with more focus on cash, restructuring and the ongoing review of options than on late stage development potential. Read on to see how this evolving narrative could matter for your own view on Fulcrum Therapeutics and how to track the next set...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By